Aligos Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aligos Therapeutics reports continued pipeline advancement in HBV, MASH, and coronavirus programs, alongside significant net losses and substantial doubt about its ability to continue as a going concern.
NASDAQ
Aligos Therapeutics, a clinical-stage biotechnology company, details its financial performance for 2024 and outlines progress in its liver disease and viral infection programs in its 10K filing.
NASDAQ
Aligos Therapeutics, a clinical-stage biopharmaceutical company, released its 10-K filing for the fiscal year ended December 31, 2023, detailing progress in its MASH and viral disease programs and financial results.